This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mascola, J. R.
Right arrow Articles by Letvin, N. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mascola, J. R.
Right arrow Articles by Letvin, N. L.

 Previous Article  |  Next Article 

Journal of Virology, January 2005, p. 771-779, Vol. 79, No. 2
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.2.771-779.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins

John R. Mascola,1* Anna Sambor,1 Kristin Beaudry,2 Sampa Santra,2 Brent Welcher,1 Mark K. Louder,1 Thomas C. VanCott,3 Yue Huang,1 Bimal K. Chakrabarti,1 Wing-Pui Kong,1 Zhi-Yong Yang,1 Ling Xu,1 David C. Montefiori,4 Gary J. Nabel,1 and Norman L. Letvin1,2

Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda,1 Henry M. Jackson Foundation, Rockville, Maryland,3 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts,2 Duke University Medical Center, Durham, North Carolina4

Received 7 June 2004/ Accepted 3 September 2004

Immunization with recombinant serotype 5 adenoviral (rAd5) vectors or a combination of DNA plasmid priming and rAd5 boosting is known to elicit potent immune responses. However, little data exist regarding these immunization strategies and the development of anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies. We used DNA plasmids and rAd5 vectors encoding the HIV-1 89.6P or chimeric HxB2/BaL envelope glycoprotein to immunize macaque monkeys. A single rAd5 immunization elicited anti-Env antibody responses, but there was little boosting with subsequent rAd5 immunizations. In contrast, rAd5 boosting of DNA-primed monkeys resulted in a rapid rise in antibody titers, including the development of anti-HIV-1 neutralizing antibodies. The potency and breadth of neutralization were evaluated by testing plasma against a panel of 14 clade B primary isolates. Moderate levels of plasma neutralizing activity were detected against about one-third of the viruses tested, and immunoglobulin G fractionation demonstrated that virus neutralization was antibody mediated. After a challenge with a chimeric simian-human immunodeficiency virus (SHIV89.6P), an anamnestic neutralizing antibody response was observed, although the breadth of the response was limited to the subset of viruses that were neutralized after the primary immunization. These data are the first detailed description of the anti-HIV-1 neutralizing antibody response in nonhuman primates elicited by DNA and rAd5 immunization. In addition to the well-established ability of DNA priming and rAd5 boosting to elicit potent anti-HIV-1 cellular immune responses, this immunization strategy elicits anti-HIV-1 neutralizing antibodies and therefore can be used to study novel Env immunogens designed to elicit more potent neutralizing antibodies.


* Corresponding author. Mailing address: Vaccine Research Center, NIAID, NIH, 40 Convent Dr., Bethesda, MD 20892. Phone: (301) 594-8490. Fax: (301) 480-2788. E-mail: jmascola{at}nih.gov.


Journal of Virology, January 2005, p. 771-779, Vol. 79, No. 2
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.2.771-779.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Haut, L. H., Ertl, H. C. J. (2009). Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J. Leukoc. Biol. 86: 779-793 [Abstract] [Full Text]  
  • Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., Birungi, J., Pozniak, A., McPhee, D. A., Manigart, O., Karita, E., Inwoley, A., Jaoko, W., DeHovitz, J., Bekker, L.-G., Pitisuttithum, P., Paris, R., Walker, L. M., Poignard, P., Wrin, T., Fast, P. E., Burton, D. R., Koff, W. C. (2009). Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm. J. Virol. 83: 7337-7348 [Abstract] [Full Text]  
  • Cayabyab, M. J., Korioth-Schmitz, B., Sun, Y., Carville, A., Balachandran, H., Miura, A., Carlson, K. R., Buzby, A. P., Haynes, B. F., Jacobs, W. R., Letvin, N. L. (2009). Recombinant Mycobacterium bovis BCG Prime-Recombinant Adenovirus Boost Vaccination in Rhesus Monkeys Elicits Robust Polyfunctional Simian Immunodeficiency Virus-Specific T-Cell Responses. J. Virol. 83: 5505-5513 [Abstract] [Full Text]  
  • Koopman, G., Mortier, D., Hofman, S., Mathy, N., Koutsoukos, M., Ertl, P., Overend, P., van Wely, C., Thomsen, L. L., Wahren, B., Voss, G., Heeney, J. L. (2008). Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian human immunodeficiency virus viraemia with protein/DNA combination. J. Gen. Virol. 89: 540-5533 [Abstract] [Full Text]  
  • Li, Y., Cleveland, B., Klots, I., Travis, B., Richardson, B. A., Anderson, D., Montefiori, D., Polacino, P., Hu, S.-L. (2008). Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses. J. Virol. 82: 638-651 [Abstract] [Full Text]  
  • Demberg, T., Florese, R. H., Heath, M. J., Larsen, K., Kalisz, I., Kalyanaraman, V. S., Lee, E. M., Pal, R., Venzon, D., Grant, R., Patterson, L. J., Korioth-Schmitz, B., Buzby, A., Dombagoda, D., Montefiori, D. C., Letvin, N. L., Cafaro, A., Ensoli, B., Robert-Guroff, M. (2007). A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques. J. Virol. 81: 3414-3427 [Abstract] [Full Text]  
  • Roy, S., Zhi, Y., Kobinger, G. P., Figueredo, J., Calcedo, R., Miller, J. R., Feldmann, H., Wilson, J. M. (2006). Generation of an adenoviral vaccine vector based on simian adenovirus 21. J. Gen. Virol. 87: 2477-2485 [Abstract] [Full Text]  
  • Mattapallil, J. J., Douek, D. C., Buckler-White, A., Montefiori, D., Letvin, N. L., Nabel, G. J., Roederer, M. (2006). Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. JEM 203: 1533-1541 [Abstract] [Full Text]  
  • Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., Koyanagi, S., Shiosaki, K., Higuchi, H., Makizumi, K., Nakashima, T., Osatomi, K., Tokiyoshi, S., Matsushita, S., Yamamoto, N., Honda, M. (2006). Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif.. J. Virol. 80: 5552-5562 [Abstract] [Full Text]  
  • Forsell, M. N. E., Li, Y., Sundback, M., Svehla, K., Liljestrom, P., Mascola, J. R., Wyatt, R., Hedestam, G. B. K. (2005). Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus. J. Virol. 79: 10902-10914 [Abstract] [Full Text]  
  • Wu, L., Kong, W.-p., Nabel, G. J. (2005). Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens. J. Virol. 79: 8024-8031 [Abstract] [Full Text]  
  • Seaman, M. S., Xu, L., Beaudry, K., Martin, K. L., Beddall, M. H., Miura, A., Sambor, A., Chakrabarti, B. K., Huang, Y., Bailer, R., Koup, R. A., Mascola, J. R., Nabel, G. J., Letvin, N. L. (2005). Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys. J. Virol. 79: 2956-2963 [Abstract] [Full Text]